Related Experiment Video
Updated: Jun 8, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Biomarkers for Early Cancer Detection - Methodological Aspects.
Paolo Verderio1, Anita Mangia, Chiara M Ciniselli
1Unit of Medical Statistics and Biometry, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Breast Care (Basel, Switzerland)
|September 18, 2010
Summary
Developing new breast cancer biomarkers for early detection requires robust analytical and clinical validation. Current practices often lack a cohesive link between these crucial validation phases, particularly in early-stage research.
Area of Science:
- Biomarker Discovery and Development
- Oncology
- Clinical Diagnostics
Background:
- Breast cancer early detection relies on validated biomarkers.
- Biomarker development involves analytical and clinical validation phases.
- Current validation practices, especially for breast cancer biomarkers, show a disconnect between analytical and clinical stages.
Purpose of the Study:
- To highlight the importance of linking analytical and clinical validation in biomarker development.
- To discuss the current state of validation for breast cancer biomarkers.
- To emphasize the need for standardized procedures in biomarker validation.
Main Methods:
- Review of existing biomarker validation schemes.
- Analysis of the relationship between analytical and clinical validation processes.
- Examination of current practices in breast cancer biomarker development.
Main Results:
- A 4-phase scheme for analytical validation of early diagnostic biomarkers has been proposed.
- Established guidelines exist for clinical validation of early diagnostic biomarkers.
- A significant gap often exists between analytical and clinical validation, particularly in early breast cancer biomarker development.
Conclusions:
- Standardized analytical validation is crucial for reliable biomarker development.
- Clinical validation provides essential assessment of biomarker impact in practice.
- Improved integration of analytical and clinical validation is necessary for effective breast cancer biomarkers.
